Drug Shortage Report for ERWINASE

Last updated on 2021-03-16 History
Report ID 22112
Drug Identification Number 02237815
Brand name ERWINASE
Common or Proper name Erwina L-asparaginase
Company Name JAZZ PHARMACEUTICALS FRANCE SAS
Market Status CANCELLED POST MARKET
Active Ingredient(s) ASPARAGINASE
Strength(s) 10000UNIT
Dosage form(s) POWDER FOR SOLUTION
Route of administration INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS
Packaging size 3 mL vials, 5 vials per carton
ATC code L01XX
ATC description OTHER ANTINEOPLASTIC AGENTS
Reason for shortage Other (Please describe in comments)
Anticipated start date 2017-09-14
Actual start date
Estimated end date Unknown
Actual end date 2021-03-10
Shortage status Resolved
Updated date 2021-03-16
Company comments Reason for ongoing shortage in Canada (less than 3-months supply) due to global capacity constraints in manufacturing leading to just-in time supply with intermittent shortages. Additionally demand has increased.
Health Canada comments
Contact Address 84 QUAI CHARLES DE GAULLE CITY ONE
LYON, AUVERGNE-RHONE-ALPES
FRANCE 69006
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v9 2021-03-16 French Compare
v8 2021-03-16 English Compare
v7 2018-02-21 French Compare
v6 2018-02-21 English Compare
v5 2018-02-21 English Compare
v4 2017-09-15 English Compare
v3 2017-09-14 French Compare
v2 2017-09-14 English Compare
v1 2017-09-14 English Compare